Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06755554

Investigation of Effect of Indocyanine Green on Volume of Lymph Node Dissection in Surgical Treatment of Gastric Cancer

Led by Ukrainian Society of Clinical Oncology · Updated on 2025-03-30

105

Participants Needed

2

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of indocyanine green (ICG) to improve the removal of lymph nodes during surgery for gastric cancer. This study focuses on patients with resectable gastric adenocarcinoma at stages Ib, II, and III. The goal is to assess the safety and benefits of using ICG in lymph node dissection, which may help achieve more complete removal of affected lymph nodes and potentially improve patient outcomes. The study is a prospective, open-label trial conducted at a single center. All participants will receive total or subtotal gastrectomy with systematic lymphadenectomy classified as D1, D1+, D2, or D2+. Before surgery, ICG is injected by endoscopic submucosal injection at four points around the tumor between 12 and 24 hours prior to the operation. During surgery, fluorescent lymph nodes labeled by ICG will be identified, removed, and mapped. The injection procedure is performed under general anesthesia, with a total ICG dose of up to 20 mg. Participants will be monitored before and after surgery for side effects related to ICG and surgical complications. Postoperative complications will be classified using Clavien-Dindo criteria. The primary outcome is the average number of lymph nodes removed during surgery, measured 30 days after the operation. Secondary outcomes include the number of fluorescent and metastatic lymph nodes and the incidence of complications within 90 days. Patients will receive standard postoperative care, including gradual resumption of fluids and physical activity, with follow-up lasting three months after surgery.

CONDITIONS

Brief Title

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Tumor spread: cT2-4a cN0-3
  • No distant metastases (cM0)
  • Age between 18 and 80 years
  • Men and women
  • ECOG performance status 0 to 1
  • Histologic type: adenocarcinoma of any subtype
  • Degree of tumor differentiation: G1 to G4
  • Tumor located in cardiac region, stomach floor, body, antrum, pylorus, or pyloric region
  • No invasion of the tumor into adjacent structures
  • No history of cancer in the past 5 years
  • No prior chemotherapy, surgery, or radiation for another cancer (except neoadjuvant chemotherapy for gastric cancer)
  • Absence of severe comorbidities limiting laparoscopic surgery
Not Eligible

You will not qualify if you...

  • Presence of distant metastases (M1)
  • ECOG performance status 2 to 4
  • Age under 18 or over 80 years
  • Presence of severe comorbidities classified as ASA greater than 3
  • Patient refusal to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Run-in Period

Duration - 12 to 24 hours before surgery

Participants receive an endoscopic injection of indocyanine green into 4 points around the tumor 24 to 12 hours before surgery to assist in lymph node mapping.

1 visit (in-person)

Treatment

Duration - Day of surgery

Participants undergo radical gastrectomy with lymph node dissection guided by fluorescence imaging from indocyanine green to remove lymph nodes and tumor tissue.

1 surgical visit (in-person)

Post-operative Follow-up

Duration - Up to 90 days after surgery

Participants are monitored for postoperative complications and recovery including assessments for side effects related to indocyanine green and surgical outcomes.

Multiple visits during 90 days post surgery

Trial Site Locations

Total: 2 locations

1

National Cancer Institute

Kyiv, Ukraine, 03022

Not Yet Recruiting

2

National Cancer Institute

Kyiv, Ukraine, 03022

Actively Recruiting

Loading map...

Research Team

O

Oleksii Dobrzhanskyi, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Phase III Randomized Controlled Trial Comparing D2 Versus D3...

Gastric Cancer

Actively Recruiting

1 location

Clinical Outcomes of Indocyanine Green Tracer in 3D Plus Ult...

Gastric Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here